- New enzyme product NuCLEANase® allows the degradation of all types of DNA/RNA
- Efficient, robust and economical solution for industrial processes in the
Food, animal feed and consumer care industry
- Enormous sales potential, since several billion markets can be addressed
Leipzig, November 11, 2021 –
c-LEcta, a global biotechnology company with technology leadership in enzyme engineering and bioprocess development, is launching a newly developed enzyme product: NuCLEANase® is a highly active endonuclease that breaks down all forms of DNA and RNA. This results in a wide range of applications in the food, animal feed and consumer care industries, with correspondingly high market potential. c-LEcta is once again demonstrating its ability to bring high quality enzyme products to market.
NuCLEANase® is a specially optimized enzyme preparation that cleaves all types of DNA. This allows DNA residues to be removed from products that are manufactured with the help of microorganisms: These include, for example, enzymes for the food and animal feed industry, but also vitamins and amino acids. Based on its proprietary technology platform ENESYZ®, c-LEcta offers this nuclease for the first time in industrial quantities, high quality and at affordable prices for all customers. NuCLEANase® supports any process that requires the removal of DNA and RNA, making it a reliable tool for various customer groups.
"Our strategy of developing our own products has paid off in recent years," emphasizes Dr. Marc Struhalla, Founder and CEO of the company. “Following the success of the Plug & Play Biocats® and the DENARASE® product family, we are now adding another attractive product to our range with NuCLEANase®, for which we are responsible for marketing and sales. NuCLEANase is another example of the power of our ENESYZ® technology platform.”
dr Biljana Mitrova, Business Development, adds: “We see great potential for our new enzyme product NuCLEANase®. NuCLEANase® is the perfect tool to support any process in industry that requires the efficient removal of remnants of genetic material, i.e. nucleic acids, or where an increase in the proportion of nucleotides is desired. In yeast products, for example: Yeasts contain many valuable nutrients - but also nucleic acids that can indirectly promote gout and kidney stones. NuCLEANase® breaks them down so that they can be easily removed.” There are other applications: in flavorings, the broken down nucleic acids improve the aroma profile in small quantities, and in larger quantities they are used in animal feed as health-promoting additives.
NuCLEANase® also enables the removal of stubborn biofilms, i.e. dirt films that settle on surfaces like plaque. After treatment with NuCLEANase®, the tough deposits dissolve more easily and can be removed efficiently. Biofilms are problematic, for example, in the food industry or in the medical environment, but also occur on human teeth and skin, so it can be expected that NuCLEANase® can also be used advantageously in personal care and cosmetic products.
Mehr Informationen: www.nucleanase.com
c-LEcta is a global biotechnology company with technology leadership in the areas of enzyme engineering and bioprocess development for regulated markets such as the food and pharmaceutical industries. The company, based in Leipzig, has established itself as a leading supplier of high-quality biotechnological products, be it in-house developments or in close cooperation with industry. c-LEcta currently employs more than 100 people.
c-LEcta delivers cost-efficient and sustainable production processes that open up new markets and enable better penetration of existing markets. The company excels at rapidly and efficiently developing best-in-class biotech solutions and successfully bringing to market and commercializing the resulting products. This allows c-LEcta to develop the unique potential of its core technologies. c-LEcta already has more than ten successfully marketed, high-quality, industrial biotech products.
Phone: +49 (0) 611 - 205855 - 35
Fax: +49 (0) 611 - 205855 - 66
Source: Press release c-LEcta from November 11.11.2021th, XNUMX